Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 5/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.40 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.40 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.40 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652165 | 0.86 | STAT3 (0.42) | SRD5A2LPAR1LPAR5STAT3PARP10 | |
| SCHEMBL5653519 | 0.85 | CYP1A2 (0.44) | — | |
| SCHEMBL5651545 | 0.85 | MMP12 (0.44) | FFAR1MMP2 | |
| SCHEMBL5653525 | 0.81 | SRD5A2 (0.44) | SRD5A2FFAR1LPAR1LPAR5FFAR4 | |
| SCHEMBL4621072 | 0.81 | SMN1; SMN2 (0.40) | LPAR1PTGDR2MMP2 | |
| SCHEMBL4623713 | 0.77 | TRPM8 (0.46) | FFAR1LPAR1FFAR4PARP10 | |
| SCHEMBL5650382 | 0.76 | MEN1 (0.46) | LPAR1LPAR5 | |
| SCHEMBL27826145 | 0.75 | TRPM8 (0.46) | — | |
| SCHEMBL5653131 | 0.73 | CYP1A2 (0.46) | FFAR1FFAR4PARP10 | |
| SCHEMBL5652505 | 0.73 | KMT2A (0.40) | STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | SRD5A2 3124/4885FFAR1 3780/4885LPAR1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.